公开(公告)号：US20180271824A1

公开(公告)日：2018-09-27

申请号：US15975323

申请日：2018-05-09

Applicant: ARRAY BIOPHARMA, INC.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D417/12 ,  C07D519/00 ,  C07D417/14 ,  C07D413/14 ,  C07D495/04 ,  A61K39/395 ,  C07D413/12 ,  C07D405/14 ,  C07D403/12 ,  C07D471/04 ,  A61K31/517 ,  A61K31/513 ,  C07D403/14

Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

公开(公告)号：US20210008023A1

公开(公告)日：2021-01-14

申请号：US16940091

申请日：2020-07-27

Applicant: Array BioPharma Inc.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/395

Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R3, R4, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

公开(公告)号：US20230142839A1

公开(公告)日：2023-05-11

申请号：US17940902

申请日：2022-09-08

Applicant: Array BioPharma Inc.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/395

CPC classification number: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/3955

Abstract: This invention provides compounds of Formula I




wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

公开(公告)号：US20170252317A1

公开(公告)日：2017-09-07

申请号：US15599867

申请日：2017-05-19

Applicant: ARRAY BIOPHARMA, INC.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00 ,  A61K31/513 ,  A61K31/517 ,  C07D403/12 ,  A61K39/395

CPC classification number: A61K31/337 ,  A61K31/513 ,  A61K31/517 ,  A61K39/3955 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.